The FOXO4-DRI price question has a clean answer and a messy one. Clean: a 10 mg vial lists at $199.99, currently sells at $134.00, and comes to $67.00 once a discount code is applied. Messy: dividing that by ten to get a cost per milligram produces a number the vendor's own laboratory reports contradict.
Key takeaways
- One vial size exists, so there is no larger-format discount to chase the way there is with compounds sold at several strengths.
- At the labelled 10 mg, $67.00 works out to $6.70 per mg. Measured net content on the two published batches was 11.41 mg and 8.30 mg, moving the real figure to roughly $5.87 or $8.07.
- Insurance is irrelevant here. There is no approved product, so there is nothing for a plan to cover and no cash-price comparison to draw.
- Bulk tiers take 3%, 5% and 10% off at three, five and ten units, and free shipping starts at $250.
- A confident single per-mg figure for this compound is a sign the writer has not opened the certificates.
The vendor we point lifters to
FOXO4-DRI from Ascension Peptides
Independently assayed material, dispatched from the US. The vial drops by half with the code below.
One vial size only, so there is no bulk-tier price break to chase on a single order. Per-mg is quoted at the labelled 10 mg: the two published batch reports measured 11.41 mg and 8.30 mg, so the real figure moves with the batch. Buying 3, 5 or 10 takes 3%, 5% or 10% off. Free shipping starts at $250. The vendor spells the product FOX04 with a zero, including in the link above.
- Batch-specific third-party lab report
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. FOXO4-DRI is not an approved medicine anywhere and has never been tested in a human trial. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified September 2, 2026.
FOXO4-DRI price, line by line
The pricing structure is short enough to state completely.
| Line | Figure |
|---|---|
| List price | $199.99 |
| Current price | $134.00 |
| With code PEPTIDEDECK | $67.00 |
| Per mg at the labelled 10 mg | $6.70 |
| Free shipping threshold | $250 |
Unlike most peptides in this market, FOXO4-DRI is sold in a single 10 mg presentation. That removes the usual optimisation. With compounds offered at two strengths there is normally a per-milligram advantage to the larger vial, and the buying decision partly becomes an arithmetic exercise. Here there is one product, and the only lever is quantity.
Buying multiples takes a percentage off the per-unit price: three units at $129.98 each, five at $127.30, ten at $120.60, which come to $389.94, $636.50 and $1,206.00 respectively. Those are reductions against the current price rather than against the discounted price, and whether a bulk tier and the code combine is worth confirming in the cart rather than assuming. The total is the only thing that settles it.
The per-milligram figure is softer than it looks
Here is where the straightforward arithmetic breaks down.
Ascension publishes two certificates for FOXO4-DRI, produced by two laboratories and covering two different batches. Kovera Labs certified batch 55-05260628 in June 2026: 99.411% purity, and net content of 11.41 mg. MZ Biolabs analysed lot 55-01260229 in January 2026: 99.97% purity, and net content of 8.30 mg. Both vials were labelled 10 mg.
Neither report is defective. They are measuring two different properties and reporting both honestly, which is more transparency than most of this market provides. But the consequence for a price comparison is direct.
| Batch | Measured net content | Effective cost per mg at $67.00 |
|---|---|---|
| Kovera 55-05260628 | 11.41 mg | about $5.87 |
| Label assumption | 10 mg | $6.70 |
| MZ Biolabs 55-01260229 | 8.30 mg | about $8.07 |
That is a spread of roughly 37% between the two published batches, invisible to anyone comparing headline prices. It also runs in the buyer's favour on one batch and against them on the other, which is worth saying plainly rather than framing the whole thing as a warning.
The honest position is that cost per milligram is a weak comparison metric for this specific compound, and a page quoting $6.70 with confidence is quoting the label rather than the material. If per-mg matters to your comparison, the number to use is the one on the certificate for your lot.
Why insurance and pharmacy pricing do not enter into it
A cost article for an approved medicine would compare cash price against copay, discuss coupons and patient assistance, and weigh telehealth programmes. None of that framework applies.
FOXO4-DRI has no marketing authorisation from the FDA, the EMA or the MHRA. There is no approved product, therefore no formulary listing, no negotiated rate, no manufacturer savings card and nothing for an insurer to reimburse. It has also never been given to a human in a registered trial, so the evidence that would normally precede any of those arrangements does not exist either.
That leaves research-supply pricing as the only pricing there is. It is set by suppliers competing on cost and, if you are fortunate, on documentation. There is no reference price to anchor against and no regulator checking the claims on the listing.
Judging whether a price is plausible
Without an anchor, the useful test is not whether a price is low but whether the documentation behind it is worth what you are paying.
A vial substantially cheaper than the rest of the market, sold with no lot number, no named laboratory and no measured content figure, is not a bargain. It is an unidentified white powder at a discount. The cost of finding out it was not what the label said is not recoverable, and there is no analytical service most buyers can practically use to check.
Conversely, a higher price does not buy quality by itself. What justifies a price in this market is the presence of a batch-specific certificate from a named laboratory, running both purity and identity methods, ideally with contamination screening, and stating measured content rather than repeating the label. Ascension does the first four for FOXO4-DRI. The contamination screening exists on one of the two published batches and not the other, which is again a batch property rather than a product guarantee.
For the reconstitution arithmetic that follows from whichever figure applies to your vial, the peptide calculator handles it, though it can only be as accurate as the content figure you feed it. Anyone comparing per-milligram costs across compounds will find the same reasoning laid out for NAD injections, where the quantities are large enough that the same label-versus-measured question has bigger consequences.
Frequently asked questions
How much does FOXO4-DRI cost?
A 10 mg vial lists at $199.99 and currently sells at $134.00. With the code PEPTIDEDECK it comes to $67.00, which is $6.70 per mg against the labelled mass. Free shipping begins at $250.
Why does the cost per milligram vary?
Because measured net content varies between batches. The two published certificates recorded 11.41 mg and 8.30 mg in vials labelled 10 mg, which puts the effective cost at roughly $5.87 or $8.07 per mg. The price does not change; the amount of peptide does.
Is there a cheaper larger vial?
No. FOXO4-DRI is sold in a single 10 mg format, so the per-milligram saving that usually comes with a larger vial is not available. Quantity discounts of 3%, 5% and 10% apply at three, five and ten units.
Will insurance cover any of it?
No. There is no approved FOXO4-DRI product in any market, so there is no indication to cover, no formulary placement and no reimbursement pathway. It is sold as laboratory research material and paid for in cash.